2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
There are two main objectives for this study. First, we will investigate the following hypothesis: Fentanyl patches provide reduction of dyspnea compared to placebo, comparable to morphine, and with less side effects than morphine. Secondly, with…